- July 12, 2018
Alan Rapoport, MD
At the American Headache Society’s 60th Annual Scientific Meeting, Dr. Alan Rapoport summarizes a poster he presented regarding ZOTRIP, Zosano Pharma’s zolmitriptan patch.
- July 9, 2018
New Effort for Lyme Disease Vaccine Draws Early Fire
In March, Valneva SE , a company based in France, announced initial phase-one clinical trial results after testing its proposed vaccine in 180 healthy adults who took the vaccine with no serious side effects. The study also showed that the vaccine stimulated an immune response, says David Lawrence, chief financial officer of the company.
- June 28, 2018
The 3 Best Biotech Stocks of 2018 So Far
Arrowhead Pharmaceuticals stock has soared more than 260% so far this year. The biotech’s share price marched steadily upward from the get-go in 2018, but Arrowhead really kicked into high gear in May after providing its second-quarter update to investors.
- June 27, 2018
Kent County’s First Medical Marijuana Dispensary to Open
Columbia Care is set to open Kent County’s first medical marijuana dispensary on Friday.
- June 7, 2018
Treatments for the Growing Problem of Hearing Loss – Sensorion’s Nawal Ouzren
- June 7, 2018
Brainstorm Considering Right To Try For ALS Therapy
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is considering offering NurOwn to treat amyotrophic lateral sclerosis under the recently enacted federal right-to-try law, BrainStorm President and CEO Chaim Lebovits told BioCentury.
- June 1, 2018
Companies to Watch: Sensorion
Sensorion is a public company in France developing new medicines for diseases of the inner ear, with two compounds in the pipeline: SENS- 111 for treating acute unilateral vestibulopathy…
- May 31, 2018
Is Hearing Loss a Necessary Price for Children to Pay for Life-Saving Chemotherapies
We spoke to Nawal Ouzren, CEO of Sensorion, which will participate in the FDA meeting and is developing a treatment for sudden hearing loss that may be able to help pediatric cancer patients experiencing cisplatin-induced ototoxicity.
